Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Eribulin mesylate

Abstract

Eribulin mesylate (Halaven; Eisai) — a synthetic analogue of the marine natural product halichondrin B that interferes with microtubule dynamics — was approved in November 2010 by the US Food and Drug Administration for the treatment of metastatic breast cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Dumontet, C. & Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nature Rev. Drug Discov. 9, 790–803 (2010).

    Article  CAS  Google Scholar 

  2. Jackson, K. L. et al. The halichondrins and E7389. Chem. Rev. 109, 3044–3079 (2009).

    Article  CAS  PubMed  Google Scholar 

  3. Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013–1021 (2001).

    CAS  PubMed  Google Scholar 

  4. Seletsky, B. M. et al. Structurally simplified macrolactone analogues of halichondrin B. Bioorg. Med. Chem. Lett. 14, 5547–5550 (2004).

    Article  CAS  PubMed  Google Scholar 

  5. Kuznetsov, G. et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 64, 5760–5766 (2004).

    Article  CAS  PubMed  Google Scholar 

  6. Jordan, M. A. et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4, 1086–1095 (2005).

    Article  CAS  PubMed  Google Scholar 

  7. Dabydeen, D. A. et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol. Pharmacol. 70, 1866–1875 (2006).

    Article  CAS  PubMed  Google Scholar 

  8. US Food and Drug Administration. FDA labelling information — Halaven. FDA website [online], http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf, (2010).

  9. Cortes, J. et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 28, 3922–3928 (2010).

    Article  CAS  PubMed  Google Scholar 

  10. Twelves, C. et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin. Breast Cancer 10, 160–163 (2010).

    Article  CAS  PubMed  Google Scholar 

  11. American Cancer Society. Cancer facts and figures 2010. ACS website [online], http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-026238.pdf, (2010).

  12. Beslija, S. et al. Third consensus on medical treatment of metastatic breast cancer. Ann. Oncol. 20, 1771–1785 (2009).

    Article  CAS  PubMed  Google Scholar 

  13. Dufresne, A. et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res. Treat. 107, 275–279 (2008).

    Article  CAS  PubMed  Google Scholar 

  14. Moreno-Aspitia, A. & Perez, E. A. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin. Proc. 84, 533–545 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Onozuka, M. Japan Equity Research (26 Jan 2011).

    Google Scholar 

  16. Sakai, F. & Tateno, T. Credit Suisse Asia Pacific/Japan Equity Research (26 Jan 2011).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huyck, T., Gradishar, W., Manuguid, F. et al. Eribulin mesylate. Nat Rev Drug Discov 10, 173–174 (2011). https://doi.org/10.1038/nrd3389

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3389

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer